Oculis (NASDAQ:OCS) Earns Buy Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Oculis (NASDAQ:OCS) in a research note released on Tuesday,Benzinga reports. They currently have a $28.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Oculis in a research report on Monday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $28.80.

Oculis Trading Up 3.2 %

Shares of NASDAQ:OCS opened at $18.22 on Tuesday. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a 52-week low of $10.50 and a 52-week high of $18.40. The stock has a market cap of $737.98 million, a price-to-earnings ratio of -9.44 and a beta of -0.33. The business has a 50-day moving average price of $16.35 and a 200-day moving average price of $13.84.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.